Medpace Q2 revenue beats estimates

Medpace Holdings

21/07/2025 21:33

Overview

Medpace Q2 2025 revenue up 14.2% to $603.3 mln, beating analyst expectations

Clinical contract research organization's GAAP net income for Q2 rises to $90.3 mln, with net income margin of 15.0%

Company repurchased 1.75 mln shares for a total of $518.5 mln in Q2 2025

Outlook

Medpace forecasts 2025 revenue between $2.420 bln and $2.520 bln

Company expects full-year GAAP net income of $405 mln to $428 mln

Medpace sees 2025 diluted EPS ranging from $13.76 to $14.53

Result Drivers

BACKLOG CONVERSION - Revenue growth represents a backlog conversion rate of 21.2%

NET NEW BUSINESS - Increase in net new business awards to $620.5 mln contributed to revenue growth

COST INCREASES - Higher direct costs and SG&A expenses impacted net income margin

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$603.31 mln
$538.80 mln (9 Analysts)
Q2 Net Income
$90.26 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Medpace Holdings Inc is $300.00, about 4% below its July 18 closing price of $311.87

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nBw8dwzvSa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)